Zhitong Finance App News, Wei Xinkang (603676.SH) issued an announcement. Recently, Yangpu Jingtai Pharmaceutical Co., Ltd. (“Yangpu Jingtai”), a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for potassium aspartate injections approved and issued by the State Drug Administration.
Potassium aspartate injection is an electrolyte supplement. It is used for hypokalemia caused by various causes. Potassium supplementation with this product can be used in combination with antihypertensive diuretics, adrenocortical hormones, cardiac glycosides, insulin, or certain antibiotics; hypokalemia; hypokalemia in the case of heart disease; severe vomiting, diarrhea, insufficient potassium ion intake, or after surgery. As of the end of March 2024, the company had invested a total of RMB 3.7542 million in research and development of this drug (unaudited).
